Susquehanna International Group’s DiaMedica Therapeutics DMAC Stock Holding History

Susquehanna International Group’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$69.7K	Buy	+10,300	New	+$81.6K	﹤0.01%	12511
2025 Q4	–	Sell	-19,600	Closed	-$135K	–	12590
2025 Q3	$135K	Buy	+19,600	New	+$106K	﹤0.01%	11366
2023 Q3	–	Sell	-10,200	Closed	-$44.1K	–	12180
2023 Q2	$44.1K	Buy	+10,200	New	+$24.8K	﹤0.01%	11385
2022 Q3	–	Sell	-59,000	Closed	-$119K	–	13337
2022 Q2	$119K	Buy	59,000 +12,500	+27%	+$29.2K	﹤0.01%	11287
2022 Q1	$116K	Buy	46,500 +33,700	+263%	+$95.6K	﹤0.01%	11790
2021 Q4	$48K	Buy	+12,800	New	+$50.3K	﹤0.01%	12567

Other funds holding DMAC

CLG

Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PAPAIJV

Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Susquehanna International Group's DMAC Position: Q1 2026 in Review

Susquehanna International Group reduced its DiaMedica Therapeutics (DMAC) stake by 51% in Q1 2026, selling an estimated $180K and leaving 21,650 shares worth $147K. The position accounts for ﹤0.01% of the portfolio, ranked #12033.

Susquehanna International Group first reported a position in DMAC in Q2 2021 and has held it in 16 quarters since. The position peaked at $2.11M in Q1 2025. 98 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

Susquehanna International Group held 21,650 shares of DiaMedica Therapeutics worth $147K as of Q1 2026.
Susquehanna International Group sold 22,736 DiaMedica Therapeutics shares in Q1 2026, an estimated $180K.
DiaMedica Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #12033 holding.
Susquehanna International Group first reported a position in DiaMedica Therapeutics in Q2 2021 and has held it in 16 quarters since.
Susquehanna International Group's DiaMedica Therapeutics position peaked at $2.11M in Q1 2025.
98 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.